FDA Panel Recommends RSV Vaccine to Protect Young Infants
An advisory panel to the Food and Drug Administration voted on Thursday in favor of …
An advisory panel to the Food and Drug Administration voted on Thursday in favor of …
BALTIMORE — The new coronavirus booster shots have found a modest number of takers at …
WASHINGTON — Federal regulators broadened access to updated coronavirus booster shots on Wednesday to include …
The Food and Drug Administration on Wednesday authorized the first redesign of coronavirus vaccines since …
The vaccines seem safe for children and are likely to protect against severe illness. But data on efficacy are thin, and most children have already been infected.
The advisers are all but guaranteed to vote yes, despite reservations about the paucity of data, especially regarding the efficacy of the Pfizer-BioNTech vaccine.
Some scientists believe that a clearer picture of Covid vaccine efficacy could have emerged sooner if investigators had tracked certain immune cells, not just antibodies.
States have already ordered millions of doses; if the agency authorizes them in the coming days, babies, toddlers and preschoolers could start receiving shots next week.
Neither Pfizers nor Modernas pediatric doses have been tested against the subvariants that may soon be dominant in the U.S.
Outside experts will make their recommendations this week on how the agency should rule on applications from Pfizer and Moderna to vaccinate the nations youngest children.
The antiviral pills, plentiful in the United States, are scarce overseas. Health groups and the White House want to expand access but face obstacles that evoke the H.I.V. epidemic.
Both Moderna and Pfizer-BioNTech have asked the agency to approve their vaccines for children under 5.